Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)

A Prospective Study for Pleural Lavage Cytology in Patients With Esophageal Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05443841

Acronym

ECTOP-2005

Enrollment

385

Registered

2022-07-05

Start date

2022-07-18

Completion date

2027-07-01

Last updated

2023-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Keywords

Squamous cell carcinoma, Esophagectomy, Pleural Lavage

Brief summary

Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis. Pleural lavage cytology (PLC) is reported to be associated with disease recurrence and patient survival in lung cancer, but the value is unclear in esophageal cancer. The aim of this study is to evaluate the value of PLC in esophageal cancer patient in terms of frequencies, association with patient survival, and efficacy of postoperative treatment.

Detailed description

Pleural lavage cytology will be performed before esophageal resection, and after resection, respectively. Frequency of positive pleural lavage cytology will be determined, and the value of pleural lavage cytology for patients with resectable esophageal cancer will be studied.

Interventions

OTHERpleural lavage

pleural lavages before tumor resection and after tumor resecion, respectively

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* esophageal cancer with histological confirmation before treatment. * resectable esophageal cancer with clinical T1-4a/N0-3/M0 staging * potential R0 resection * no history of other malignancies

Exclusion criteria

* severe major organ dysfunction (American society of anesthesiologisits score \>3 ) * patients underwent ESD or EMR * pleural lavage is unavailable due to adhesions

Design outcomes

Primary

Measure	Time frame	Description
number of patients who had positive pleural lavage cytology	July 2022 to July 2023	Frequency of positive pleural lavage cytology in resectable esophageal squamous cell carcinoma

Secondary

Measure	Time frame	Description
Time period from date of surgery to the date of death	July 2022 to July 2026	value of pleural lavage cytology in predict patient survival

Countries

China

Contacts

Primary ContactBin Li, MD

lb0256327@hotmail.com086-64175590-82500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026